ImmunoForge Selected for Global R&D Program

ImmunoForge has been chosen to participate in the Korean Ministry of SMEs and Startups' "Global TIPS R&D" program. This selection recognizes the company's Leptin receptor-based technology and its hybrid lipid nanoparticle (LNP) platform.

The program will support the development of ImmunoForge's technology, which combines the ability to penetrate the blood-brain barrier with a sustained-release formulation lasting up to one month. The company stated this technology has demonstrated its potential by winning first place in a competition.

Participation in the "Global TIPS R&D" program is expected to provide ImmunoForge with resources and support to advance its technology towards therapeutic applications, particularly for central nervous system disorders.

The company aims to leverage this technological advancement to develop new treatment modalities for neurological conditions.